CYP2D6 polymorphisms influence tamoxifen treatment outcomes in
Por um escritor misterioso
Descrição
Frontiers Physiologically-based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance
CYP2D6 polymorphisms and their influence on risperidone treatment. - Document - Gale OneFile: Health and Medicine
Effects of CYP2D6 Genetic Polymorphism and Drug Interaction on the Metabolism of Dacomitinib
Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes
Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer, Egyptian Journal of Medical Human Genetics
Full article: CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis
CYP2D6 Genotype–Guided Tamoxifen Dosing in Hormone Receptor–Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study
Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives - ScienceDirect
